Centre Leon Berard
Centre Leon Berard
Lyon, France70 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | cancer, neoplasm | Active, not recruiting | Phase 3 | 2026-10-08 | NCT03148418 | |
| A Study of Sofe-M in Participants With Selected Advanced Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cervix disorder, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, triple-negative breast carcinoma, uterine disorder | Recruiting | Phase 1 | 2026-10-07 | NCT06400472 | |
| A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Richter transformation, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT05006716 | |
| A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | cancer, neoplasm | Recruiting | Phase 3 | 2026-10-02 | NCT05862285 | |
| Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, breast carcinoma in situ, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01272037 | |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-30 | NCT06765109 | |
| Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC | mCRPC | Active, not recruiting | Phase 3 | 2026-09-29 | NCT03395197 | |
| A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-09-28 | NCT07277231 | |
| A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors | Advanced-stage Solid Tumors | Recruiting | Phase 1 | 2026-09-28 | NCT07223125 | |
| Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06073821 | |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-09-28 | NCT04722146 | |
| A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC | Metastatic Castrate-sensitive Prostate Cancer | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05884398 | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Stomatognathic Diseases, Thyroid Cancer, Papillary, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenocarcinoma, benign urinary system neoplasm, brain disorder, carcinoma, central nervous system cancer, central nervous system disorder, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, glioma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, malignant endocrine neoplasm, medulloblastoma, mesoblastic nephroma, mixed neoplasm, mouth disorder, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, papillary adenocarcinoma, primitive neuroectodermal tumor, salivary gland cancer, salivary gland disorder, sarcoma, thyroid gland disorder, thyroid tumor, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT02650401 | |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07213674 | |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Adnexal Diseases, Carcinoma, Ductal, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, appendiceal neoplasm, bronchial disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cecal disorder, cecal neoplasm, colonic disorder, colonic neoplasm, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm, stomach disorder, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT06128551 | |
| A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-09-16 | NCT06497556 | |
| Contribution of Multicenter Expertise and Deformable Fusion Software for Re-irradiations With Curative Intent | Radiotherapy; Re-irradiation | Recruiting | Not applicable | 2026-09-15 | NCT06668038 | |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-09-14 | NCT07739459 | |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Active, not recruiting | Phase 3 | 2026-09-14 | NCT06065748 | |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 2 | 2026-09-10 | NCT04931342 | |
| First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Bites and Stings, Chemically-Induced Disorders, Neoplasms by Site, Thoracic Neoplasms, injury, lung disorder, lung neoplasm, neoplasm, poisoning, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-09-09 | NCT05361395 | |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2026-09-08 | NCT05307705 | |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04821622 | |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Solid Tumors | Active, not recruiting | Phase 2 | 2026-09-04 | NCT04589845 | |
| A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement | FGFR2 Gene Fusion/Rearrangement; Other Solid Tumors, Adult | Recruiting | Phase 2 | 2026-09-03 | NCT07359820 |